PTGX - protagonist-inc.com Full Takeover Company Value
This price trend reflects the enterprise value of Protagonist Therapeutics (PTGX), which currently stands at 8424.27. The high margin potential of Protagonist Therapeutics (PTGX) is protected by patents for innovative peptides. The business is based on creating oral drug formulations that combine antibody properties with ease of administration, which is highly sought after in the therapy of rare blood pathologies. The company's strategy relies on integrating cutting-edge developments into the product lines of global pharmaceutical behemoths.
%20Real%20Price%20to%20Acquire%20Entire%20Company&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_PTGX_-_Protagonist-Therapeutics_-_Real-Price-to-Acquire-Entire-Company "PTGX (Protagonist) Business Value history from 11/23/2025 to 10/29/2026 | 👁️GURU.Markets👁️")
Protagonist Therapeutics (PTGX) - metric breakdowns and financial figures
- current price and projected stock value:
- market capitalization statistics:
- company book value details:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Protagonist Therapeutics|PTGX - Long-Term Debt to Capital|Short-Term Debt to Capital protagonist-inc.com|PTGX - Company Debts|Debt to Net Assets Ratio Protagonist Therapeutics|PTGX - Company Long-Term Debt|Company Current Liabilities Protagonist Therapeutics|Quick Ratio protagonist-inc.com
- earnings and valuation multiples indicators:
Analysis of all company metrics:Protagonist Therapeutics, Inc.
Retaining key peptide biotechnology specialists and the R&D core of Protagonist Therapeutics (PTGX) creates a long-term intellectual asset that is capitalized into the business value. The current value of 8424.27 reflects the total acquisition cost of the company, combining market capitalization with net debt, which allows for an assessment of the real price for acquiring all operational capacities through the EV history.
Competitors of Protagonist Therapeutics (PTGX)
Aggregate Business Value ARGX (argenx N.V.)|BioNTech Group - Enterprise Value|Full Takeover Company Value Abivax Pharma (ABVX)|ADMA (ADMA Biologics) - Real Price to Acquire Entire Company|Business Value IMVT|Total Company Value Kiniksa|Grifols SA - Full Business Value|Enterprise Value ADPT|CLDX (Celldex Corp) - Value Adjusted for Debt and Cash|Enterprise Value AUPH (Aurinia Pharmaceuticals)|Enterprise Value biocryst.com BCRX|VERA - Total Company Value|Value Adjusted for Debt and Cash DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp (PHVS) - Total Company Value|Real Price to Acquire Entire Company AbCellera Biologics Inc.|TRML (Tourmaline Bio, Inc.) - Enterprise Value|Enterprise Value precigen.com|Real Price to Acquire Entire Company PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Value Adjusted for Debt and Cash|Enterprise Value UPB (Upstream Bio Corp)|Company Buyout Price Zenas Corp (ZBIO)|IMNM - Total Company Value|gossamerbio.com (GOSS) - Real Price to Acquire Entire Company|KalVista Pharmaceuticals, Inc. (KALV) - Total Company Value|Real Price to Acquire Entire Company Septerna, Inc.|Real Price to Acquire Entire Company PVLA|Enterprise Value Savara Pharma|Total Company Value Rigel Pharmaceuticals (RIGL)|anaptysbio.com - Business Value|Enterprise Value ATXS (Astria Therapeutics, Inc.)|enGene Holdings Inc (ENGN) - Total Enterprise Value|RAPT - Total Company Value|Full Business Value JBIO|Aclaris Therapeutics (ACRS) - Total Company Value|kyvernatx.com - Value Adjusted for Debt and Cash|Total Company Value Tiziana Life Sciences Ltd|Total Enterprise Value Cabaletta Bio Inc. CABA|Real Price to Acquire Entire Company VTYX (Ventyx Bio)|Aggregate Business Value THTX|Enterprise Value AVTX (Avalo Therapeutics, Inc)|Enterprise Value eledon.com ELDN|Agenus Inc. - Enterprise Value|Full Takeover Company Value Climb Bio Inc. (CLYM)|Zura Bio (ZURA) - Total Company Value|Total Enterprise Value aTyr Pharmaceuticals (ATYR)|Total Company Value Adagene Inc|Business Value IMA (Ikena Oncology, Inc.)|Enterprise Value STTK|Company Buyout Price equilliumbio.com|Total Company Value Connect Biopharma Holdings Limited CNTB|Company Buyout Price Immunic Therapeutics (IMUX)|ATRA: Real Price to Acquire Entire Company|InflaRx N.V. - Aggregate Business Value|XFOR (X4 Pharmaceuticals, Inc.) - Real Price to Acquire Entire Company|Adicet Bio, Inc. - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company CELU|INMB (INmune Bio Corporation) - Aggregate Business Value|Enterprise Value BRNS|KZR (kezarlifesciences.com) - Value Adjusted for Debt and Cash|Enterprise Value SABS (SAB Biotherapeutics, Inc.)|Akari Therapeutics PLC (AKTX) - Total Enterprise Value|ENLV - Total Company Value|Value Adjusted for Debt and Cash QTTB (Q32 Bio Inc.)|GOVX: Enterprise Value|edesabiotech.com (EDSA) - Enterprise Value|Total Company Value iBio|Carisma Tx - Full Business Value|Enterprise Value XTLB|BOLT - Total Enterprise Value|HCW Biologics - Real Price to Acquire Entire Company|Enterprise Value Aptevo Therapeutics, Inc. APVO|AIM: Real Price to Acquire Entire Company|Aditxt - Aggregate Business Value|GRI: Enterprise Value|XRTX - Company Buyout Price|HIND (Vyome Holdings Inc) - Enterprise Value|Real Price to Acquire Entire Company revbiosciences.com (REVB)|Total Company Value Indaptus Therapeutics, Inc. (INDP)|Company Buyout Price Scinai Immunotherapeutics Ltd|Total Company Value CalciMedica CALI|AFMD (Affimed NV) - Full Business Value|ALLK: Real Price to Acquire Entire Company|HOOKIPA Pharma Inc. - Aggregate Business Value|IGMS: Enterprise Value|Full Takeover Company Value iTeos Therapeutics Inc ITOS|Real Price to Acquire Entire Company OCEA|Business Value TCBP (TC BioPharm Ltd)|Total Company Value Third Harmonic Bio (THRD)